A Phase 1 interventional study of Caffeine and Dextromethorphan in Pharmacokinetics of Dextromethorphan, Pharmacokinetics of Caffeine and Prostate Cancer, sponsored by Astellas Pharma Europe B.V.. Completed at 1 site in Moldova, Republic of. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-27.
Sponsored by Astellas Pharma Europe B.V. (part of Astellas Pharma Inc) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Prostatic Neoplasms by Astellas Pharma Inc — 5 open to participants now, 7 under way, 1 of them phase 3. Prostatic Neoplasms · Astellas Pharma Inc.
Among the 53 studies in Prostatic Neoplasms by Astellas Pharma Inc, this one is the 35th largest by enrollment of the 39 interventional ones that give a count, is one of 4 that started in 2013, is one of 12 in phase 1, and was the 30th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →5 of the 53 studies in Prostatic Neoplasms by Astellas Pharma Inc are open now, in 12 countries. Recruiting first, the newest first:
Astellas Pharma Global Development, Inc. · Sites in Bulgaria
Ages 50–75 · Men only · Healthy volunteers
Astellas Pharma Global Development, Inc. · Sites in China
Ages 18–85 · Men only
Astellas Pharma Global Development, Inc. · Sites in United States, China, France and 9 more countries
Ages 18+ · Men only
Astellas Pharma Global Development, Inc. · Sites in United States, Australia, Spain and 1 more country
Ages 18+ · Men only
Astellas Pharma Global Development, Inc. · Sites in United States, Puerto Rico
Ages 18+ · Men only
By country, each count listing its studies:
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 17 · Phase 3 6 · Phase 4 7
First in 2001; this study’s year is marked. 4 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 67 across the 39 interventional studies, 1,018 across the 11 observational. Of the 46 that completed or were terminated, 13 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Astellas Pharma Europe B.V., one of the names counted as Astellas Pharma Inc. Under that name alone:
Astellas Pharma Europe B.V. is the lead sponsor of 94 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
2 of the studies in Prostatic Neoplasms by Astellas Pharma Inc that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07783282Astellas Pharma Global Development, Inc.A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed in Men With Prostate Cancer | 2027-04-30 |
| NCT05997615Astellas Pharma Global Development, Inc.Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 53 studies in Prostatic Neoplasms by Astellas Pharma Inc, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluates how once daily enzalutamide affects the metabolism of caffeine and dextromethorphan in men with prostate cancer by measuring concentrations of these drugs and their metabolites in plasma.
This is an open-label, fixed-sequence, crossover drug-drug interaction study in subjects with prostate cancer.
Screening takes place between Day -28 and Day -7, and subjects are admitted to the clinic on Day -1 where they remain until Day 4.
On Day 1, they receive a single oral cocktail containing caffeine and dextromethorphan plus a dose of enzalutamide placebo in order to assess possible effects of excipients of the enzalutamide formulation. On Days 1 to 3 blood samples for pharmacokinetic (PK) assessment are collected. From Days 4 to 54, (or Day 55 if the subject rolls over into the extension study) the subjects take a daily oral dose of enzalutamide. On Day 28, the subjects return to the clinic where a plasma sample is taken to determine enzalutamide PK exposure. From Days 52 to 55 they are re-admitted to the clinic where a plasma sample is collected on Day 52 for enzalutamide PK exposure.On Day 53, subjects receive a single oral cocktail of caffeine and dextromethorphan concomitantly with enzalutamide. PK samples are collected from Days 53 to 55.
From Day 55 onwards, subjects experiencing clinical benefit may roll over into an extension study. Only subjects who enroll into the extension study continue to receive enzalutamide otherwise daily dosing with enzalutamide is discontinued on Day 54.
An End of Study Visit (ESV) takes place approximately 30 days (±7 days) after the last dose of enzalutamide.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1-sequence crossover here
Drug: Caffeine · Drug: Dextromethorphan · Drug: Enzalutamide · Drug: Enzalutamide Placebo to Match (PTM)
Oral
Also known as: CYP1A2 substrate
Oral /.L
Also known as: CYP2D6 substrate
Oral
Also known as: Xtandi, MDV3100, ASP9785
Oral
PK measured by Pharmacokinetic parameter Maximum concentration (Cmax)
For the probe substrates (caffeine and dextromethorphan) in combination with enzalutamide PTM and in combination with enzalutamide.
Time frame: Day 1 and Day 53 (28 times)
PK measured by Pharmacokinetic parameter Area under the curve (AUC) from the time of dosing to the last measurable concentration (AUC0-t)
For the probe substrates (caffeine and dextromethorphan) in combination with enzalutamide PTM and in combination with enzalutamide.
Time frame: Day 1 and Day 53 (28 times)
PK measured by PK parameter area under the curve (AUC) from time 0 extrapolated to infinity (AUC0-inf)
For the probe substrates (caffeine and dextromethorphan) in combination with enzalutamide PTM and in combination with enzalutamide.
Time frame: Day 1 and Day 53 (28 times)
PK measured by PK parameters tmax, terminal elimination half-life (t1/2), apparent total systemic clearance after oral dosing (CL/F), apparent volume of distribution during terminal elimination phase (Vz/F) and extrapolated AUC (%AUC)
Tmax is time to maximum concentration. These PK parameters will be measured for the probe substrates (caffeine and dextromethorphan) in combination with enzalutamide PTM and in combination with enzalutamide.
Time frame: Day 1 and Day 53 (28 times)
PK measured by PK parameters Cmax, AUC0-t, AUC0-inf, %AUC, tmax and t1/2
For 1,7-dimethylxanthine (metabolite caffeine), dextrorphan (metabolite dextromethorphan).
Time frame: Day 1 and Day 53 (28 times)
PK measured by PK parameters Cmax, trough concentrations (Ctrough) at Days 28, 52, 53, 54 and 55, tmax, AUC during the time interval between consecutive dosing (AUCtau), CL/F (parent only) and peak-to-trough ratio (PTR)
For Enzalutamide, N-desmethyl enzalutamide (M2) and sum of enzalutamide + M2.
Time frame: Day 28 (± 1 day), and Days 52 to 55 (15 times)
Safety and tolerability measured by vital signs, adverse events, laboratory assessments and electrocardiogram
Time frame: Screening (Day -28 to Day -7) to ESV (>153 times)
Ran from Oct 2013 to primary completion in Feb 2014, 4 months.
Of 212 industry-sponsored phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's 4 months is below that.
Counting every sponsor, half of 456 studies reached it within 43 months; a quarter within 23 and three quarters within 68.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Caffeine · Dextromethorphan · Enzalutamide